Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Protein-Drug Binding: Mechanism and Kinetics

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...

Cooperative Allosteric Transitions

Cooperative Allosteric Transitions

Receptor Tyrosine Kinases

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

The Equilibrium Binding Constant and Binding Strength

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:

Ligand Binding and Linkage

Ligand Binding and Linkage

Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Protein-ligand binding kinetics are primarily controlled by the protein, not the ligand.

bioRxiv : the preprint server for biology·2026

Same author

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States.

ChemMedChem·2026

Same author

From memorization to generalization: Why physics will improve machine learning -based prediction of protein complexes.

Current opinion in structural biology·2026

Same author

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

bioRxiv : the preprint server for biology·2026

Same author

A synergistic interaction between PRMT5 and LSD1 inhibitors in AML.

Science advances·2026

Same author

Discovery of Covalent Ligands with AlphaFold3.

Journal of the American Chemical Society·2026

Search research articles

Related Experiment Video

Updated: Sep 13, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Modulating the Binding Kinetics of Bruton's Tyrosine Kinase Inhibitors through Transition-State Effects.

Eduardo Bravo¹, Yong Li¹, David Yin-Wei Lin²

¹Center for the Advanced Study of Drug Action, Department of Chemistry, Stony Brook University, Stony Brook, New York 11794-3400, United States.

Journal of the American Chemical Society

|July 29, 2025

Summary

This study introduces a knowledge-based method to design Bruton's tyrosine kinase (BTK) inhibitors with controlled binding kinetics. The research yields novel inhibitors with extended residence times, improving therapeutic potential for B-cell malignancies and autoimmune diseases.

More Related Videos

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Related Experiment Videos

Last Updated: Sep 13, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Area of Science:

Biochemistry
Medicinal Chemistry
Pharmacology

Background:

Optimization of small molecules aims to enhance target efficacy and selectivity while minimizing off-target effects.
Engineering kinetic selectivity, alongside thermodynamic selectivity, is crucial for biological systems but challenging to achieve rationally.
Bruton's tyrosine kinase (BTK) is a key target for treating B-cell malignancies and autoimmune diseases.

Purpose of the Study:

To develop a systematic, knowledge-based approach for designing inhibitors with modulated binding kinetics for BTK.
To investigate the relationship between inhibitor structure, BTK-inhibitor interactions, and the kinetics of enzyme inhibition.
To engineer BTK inhibitors with extended residence times by uncoupling kinetic parameters from equilibrium affinity.

Main Methods:

Detailed kinetic assessment of existing BTK inhibitors.
Structural studies to elucidate BTK-inhibitor interactions governing inhibition kinetics.
Design and synthesis of pyrazolopyrimidine-based inhibitors targeting the kinase back pocket's R-spine interactions.
Evaluation of inhibitor binding kinetics (k_on, k_off) and equilibrium affinity.

Main Results:

Identification of key BTK-inhibitor interactions influencing binding kinetics.
Successful design of pyrazolopyrimidine inhibitors that modulate transition state stability.
Development of BTK inhibitors exhibiting significantly extended residence times.
Demonstration that kinetic parameters (k_on, k_off) can be modulated independently of equilibrium affinity.

Conclusions:

A systematic approach can rationally design inhibitors with specific kinetic profiles.
Modulating interactions with the R-spine is a viable strategy for engineering inhibitor residence time.
The developed BTK inhibitors with extended residence times offer potential for improved therapeutic outcomes in B-cell malignancies and autoimmune diseases.